Forskolin

1. What conditions has Forskolin been studied for?

• Cancer (general anticancer mechanisms): Reviewed as a cAMP-elevating compound with relevance to tumor biology (via adenylate cyclase → cAMP → PKA-dependent/independent signaling).

• Non-small-cell lung cancer (NSCLC): Studied in vitro in H1299 and A549 cell lines, alone and with paclitaxel.

• Obesity / metabolic disease: Studied in a nanomedicine formulation to induce “browning” of white adipocytes and prevent weight gain in high-fat diet mice; also assessed for glucose uptake and lipolysis.

• Vitiligo / melanogenesis support: Studied in melanocyte models in combination with roflumilast (a PDE4 inhibitor) to raise cAMP and promote melanogenesis.

• Liver fibrosis: Studied in a rat model of CCl4-induced hepatic fibrosis as a hedgehog (Hh) signaling inhibitor with antioxidant/anti-inflammatory effects.

• Diabetic retinopathy (prevention/early biomarkers): Studied in diabetic mice as a GLUT1 inhibitor to reduce retinal glucose and early retinopathy biomarkers (e.g., superoxide radicals, β2 crystallin, VEGF).

• Glaucoma / intraocular pressure (IOP) and retinal function: Mentioned in a review of nutritional interventions where supplements containing forskolin “consistently” reduced IOP beyond standard therapy; also tested in a mouse optic nerve crush model as part of a multi-ingredient supplement improving an electrophysiologic marker tied to retinal ganglion cell integrity (PhNR).

• Diabetes / hyperglycemia and oxidative stress: Studied in streptozotocin-induced diabetic rats for fasting glucose and urinary 8-OHdG (oxidative DNA damage marker).

• Hypertrophic cardiomyopathy (HCM): Studied in mouse models; abstract reports mitigation of cardiac hypertrophy (details truncated).

• Oral submucous fibrosis (OSMF): Studied preclinically; prior work cited that forskolin plus photobiomodulation reduced arecoline-induced fibrotic reactions via cAMP pathway (animal model development noted; details truncated).

• Naegleria fowleri infection (primary amoebic meningoencephalitis; preclinical): In vitro testing of forskolin alone and in combination (notably with thymol or borneol) for amoebicidal activity and synergy.

2. Does it work in treating those conditions? Summarize the evidence.

• Cancer (general): The oncology-focused review argues that elevating cAMP can produce antitumor effects (e.g., inhibiting growth/migration, inducing mesenchymal-to-epithelial transition, increasing sensitivity to conventional drugs). This is mechanistic and preclinical in nature; it does not establish clinical efficacy.

• NSCLC (cell culture): In H1299 and A549 cells, forskolin impaired cell growth and migration and altered cell-cycle progression and epithelial–mesenchymal markers. Comparable growth impairment occurred with IBMX (a phosphodiesterase inhibitor), while an adenylyl cyclase inhibitor (SQ22536) partially counteracted forskolin’s effects—supporting involvement of the adenylyl cyclase/cAMP axis. Forskolin also “strongly enhances” paclitaxel-induced cytotoxicity, mainly via apoptosis; PKA inhibition (H89) further altered the combination outcome. This is promising but limited to in vitro data.

• Obesity/metabolic effects (nanomedicine; mice + human adipocytes in vitro): A lipid-silica nanohybrid delivering forskolin induced browning/thermogenic markers in mature human adipocytes in vitro and in mice, reporting very large increases in UCP1 and Cox7A1 in vivo (400-fold and 80-fold, respectively). It also acutely enhanced glucose uptake and lipolysis and significantly prevented weight gain in high-fat diet mice compared with other treatments (including a liposomal medicine). This supports efficacy in a specific formulation and model; it does not directly prove that standard oral forskolin supplements produce similar outcomes in humans.

• Vitiligo-related melanogenesis (cell-based): Roflumilast alone only slightly increased melanogenesis, but roflumilast + forskolin boosted cAMP and promoted melanogenesis more significantly than roflumilast alone. This supports a synergistic, mechanism-based approach in vitro; clinical benefit in vitiligo patients is not established by these studies.

• Liver fibrosis (rat model): In a CCl4-induced fibrosis model, forskolin exerted “promising antifibrotic effects,” attributed partly to antioxidant/anti-inflammatory actions and inhibition of hedgehog signaling mediated by cAMP-dependent PKA activation. This is animal evidence; translation to human liver fibrosis treatment remains uncertain.

• Diabetic retinopathy prevention (diabetic mice): Systemic forskolin reduced retinal glucose to non-diabetic levels, similar to GLUT1 siRNA knockdown. Importantly, 1,9-dideoxyforskolin (binds GLUT1 but does not stimulate adenylate cyclase) had an equivalent retinal glucose-lowering effect, indicating cAMP was “noncontributory” for this endpoint. Forskolin also prevented early biomarkers of retinopathy (superoxide radicals, β2 crystallin, VEGF). This is strong preclinical evidence for a GLUT1-mediated mechanism; it is not yet clinical proof.

• Glaucoma / IOP (human evidence suggested but not conclusive): A review of 33 intervention trials (21 RCTs) states that supplements containing forskolin have “consistently demonstrated” IOP reduction beyond traditional therapy alone, but concludes evidence is not conclusive and higher-quality research is needed. Another study in a mouse optic nerve crush model found a multi-ingredient supplement (including forskolin) prevented reduction of PhNR amplitude (a functional marker linked to retinal ganglion cell integrity), but the effect cannot be attributed to forskolin alone.

• Diabetes / fasting glucose (rat study): In streptozotocin-diabetic rats, chronic daily forskolin for 8 weeks lowered fasting glucose at the end of the experiment; in healthy rats it also lowered fasting glucose but did not affect oral glucose tolerance. Urinary 8-OHdG tended to be less elevated, but reductions were not statistically significant. This suggests possible fasting glucose benefit in this model, with mixed oxidative-stress findings.

• Naegleria fowleri (in vitro): Forskolin combined with thymol or borneol showed synergistic effects against trophozoites (e.g., forskolin + thymol IC50 ~81.3 μM at 24h) and minimal cytotoxicity in several human cell lines in LDH assays. Authors emphasize the need for in vivo animal studies and exploration of intranasal delivery.

• HCM and OSMF: Both are described as preclinical with positive signals (mitigation of hypertrophy in mouse models for HCM; reduced fibrosis reactions via cAMP pathway for OSMF), but the studies reviewed here are truncated and do not allow a full evidence appraisal.

3. What health benefits does it have?

• cAMP elevation and signaling modulation: Forskolin directly activates adenylate cyclase, increasing intracellular cAMP, which is implicated in multiple downstream pathways (PKA-dependent and/or independent). The cancer review highlights potential antitumor-relevant effects of cAMP signaling such as reduced growth/migration and increased sensitivity to standard anticancer drugs (preclinical rationale).

• Potential anticancer activity (preclinical): In NSCLC cell lines, forskolin reduced growth and migration and enhanced paclitaxel cytotoxicity via apoptosis (in vitro).

• Metabolic effects (preclinical, formulation-dependent): In a nanomedicine context, forskolin promoted adipocyte “browning,” increased thermogenesis biomarkers (UCP1, Cox7A1), enhanced glucose uptake and lipolysis acutely, and prevented weight gain in high-fat diet mice.

• Retinal glucose lowering and retinopathy biomarker prevention (preclinical): In diabetic mice, forskolin reduced retinal glucose via GLUT1 inhibition and prevented early diabetic retinopathy biomarkers (superoxide radicals, β2 crystallin, VEGF).

• Intraocular pressure lowering (suggestive clinical literature): A glaucoma nutrition review reports that forskolin-containing supplements have consistently lowered IOP beyond standard therapy, though overall evidence remains inconclusive.

• Possible antifibrotic effects (animal): In rat liver fibrosis, effects were linked to antioxidant/anti-inflammatory actions and hedgehog signaling inhibition via cAMP/PKA.

• Possible support of melanogenesis (cell-based): Forskolin combined with a PDE4 inhibitor (roflumilast) increased cAMP and melanogenesis more than roflumilast alone, suggesting a pathway-relevant approach for pigment restoration research.

• Fasting glucose lowering (animal): Chronic administration lowered fasting glucose in both diabetic and healthy rats in one study, though without improving OGTT in healthy rats.

4. Does it have any downsides or side effects?

• Human side effects are not well-characterized in the studies reviewed here: Most evidence here is in vitro, animal, or review-level discussion; adverse event reporting is limited.

• Evidence gaps and formulation issues: Some positive findings are tied to specific delivery systems (e.g., lipid-silica nanohybrid) or multi-ingredient supplements (glaucoma mouse study), so benefits and risks may not generalize to typical over-the-counter oral forskolin products.

• Mechanism-based caution (theoretical): Because forskolin increases cAMP broadly, it could plausibly have wide physiological effects depending on tissue context. However, the studies reviewed here do not quantify common clinical side effects (e.g., cardiovascular, gastrointestinal) or drug–supplement interactions.

• Cytotoxicity signals (limited): In the Naegleria study, forskolin-containing combinations showed minimal cytotoxicity in several human cell lines (HaCaT, HeLa, SH-SY5Y) by LDH release testing, which is reassuring for that specific in vitro context but does not establish systemic safety in humans.

• “Safety documented” claim is not detailed: The cancer review states forskolin’s safety has been documented in conventional modern medicine, but the study does not provide specific safety outcomes, doses, or trial data.

5. Is it beneficial or harmful for any genetic variations (pharmacogenomics)?

The studies reviewed here do not present direct pharmacogenomic evidence (i.e., outcomes stratified by human genetic variants) for forskolin response or toxicity.

• Mechanistic note (not pharmacogenomics per se): Forskolin’s canonical mechanism is adenylate cyclase activation → increased cAMP → downstream signaling (including PKA). In NSCLC cells, blocking adenylyl cyclase partially counteracted effects, supporting pathway dependence. This suggests that variation in genes within the cAMP pathway (adenylyl cyclase isoforms, phosphodiesterases, PKA subunits) could theoretically influence response, but this is not tested in the studies.

• GLUT1-related mechanism in diabetic retinopathy model: One mouse study indicates forskolin can act via GLUT1 inhibition independent of cAMP (since 1,9-dideoxyforskolin had equivalent effects). This implies that variation in GLUT1/SLC2A1 could theoretically matter for retinal glucose effects, but no genotype-response data are provided.

• HCM is genetic by definition, but details are missing: The HCM abstract mentions mouse models tied to a pathogenic variant and reports forskolin mitigated hypertrophy, but the truncated text does not allow conclusions about variant-specific benefit, nor does it establish relevance to human carriers.

References

1. The Natural cAMP Elevating Compound Forskolin in Cancer Therapy: Is It Time?
   Luigi Sapio, Monica Gallo, Michela Illiano, Emilio Chiosi, Daniele Naviglio, Annamaria Spina, Silvio Naviglio (2017) - Journal of cellular physiology
2. Local administration of lipid-silica nanohybrid-carried forskolin modulates thermogenesis in human adipocytes and impedes weight gain in mice.
   David Zhang, Lien Tang, Tyler Hipple, Curtis D Mowry, C Jeffrey Brinker, Eric Brey, Achraf Noureddine, Maria A Gonzalez Porras (2025) - Advanced functional materials
3. Roflumilast enhances the melanogenesis and attenuates oxidative stress-triggered damage in melanocytes.
   Zile Chen, Yiting Li, Yongyi Xie, Shu Nie, Bin Chen, Zhouwei Wu (2023) - Journal of dermatological science
4. Forskolin, a hedgehog signalling inhibitor, attenuates carbon tetrachloride-induced liver fibrosis in rats.
   Nermeen N El-Agroudy, Reem N El-Naga, Rania Abd El-Razeq, Ebtehal El-Demerdash (2016) - British journal of pharmacology
5. Anti-Melanogenesis Effect of Polysaccharide from
   Mayila Kamilijiang, Deng Zang, Nuermaimaiti Abudukelimu, Nurbolat Aidarhan, Geyu Liu, Haji Akber Aisa (2022) - Nutrients
6. Forskolin affects proliferation, migration and Paclitaxel-mediated cytotoxicity in non-small-cell lung cancer cell lines via adenylyl cyclase/cAMP axis.
   Alessia Salzillo, Angela Ragone, Annamaria Spina, Silvio Naviglio, Luigi Sapio (2023) - European journal of cell biology
7. Suppression of GLUT1; a new strategy to prevent diabetic complications.
   Lili Lu, Christopher P Seidel, Takeshi Iwase, Rebecca K Stevens, Yuan-Yuan Gong, Xinyi Wang, Sean F Hackett, Peter A Campochiaro (2013) - Journal of cellular physiology
8. Nutritional supplementation in the treatment of glaucoma: A systematic review.
   Ekaterina Loskutova, Colm O'Brien, Igor Loskutov, James Loughman (2019) - Survey of ophthalmology
9. Natural Terpenes Inhibit the Cytopathogenicity ofNaegleria fowleriCausing Primary Amoebic Meningoencephalitis in the Human Cell Line Model
   Kavitha Rajendran, Usman Ahmed, Alexia Chloe Meunier, Mohd Farooq Shaikh, Ruqaiyyah Siddiqui (2023)
10. Protective Efficacy of a Dietary Supplement Based on Forskolin, Homotaurine, Spearmint Extract, and Group B Vitamins in a Mouse Model of Optic Nerve Injury.
    Filippo Locri, Maurizio Cammalleri, Massimo Dal Monte, Dario Rusciano, Paola Bagnoli (2019) - Nutrients
11. Effect of chronic administration of forskolin on glycemia and oxidative stress in rats with and without experimental diabetes.
    Mónica Ríos-Silva, Xóchitl Trujillo, Benjamín Trujillo-Hernández, Enrique Sánchez-Pastor, Zorayda Urzúa, Evelyn Mancilla, Miguel Huerta (2014) - International journal of medical sciences
12. Forskolin is an effective therapeutic small molecule for the treatment of hypertrophic cardiomyopathy through ADCY6/cAMP/PKA pathway.
    Wenyan Wang, Yingying Xue, Dujuan Li, Chenwen Shao, Kejia Wu, Ning Sun, Qi Chen (2024) - European journal of pharmacology
13. Photobiomodulation therapy inhibits oral submucous fibrosis in mice.
    Min-Hsuan Chiang, Kun-Tsung Lee, Chia-Hsin Chen, Ker-Kong Chen, Yan-Hsiung Wang (2020) - Oral diseases
14. Biotechnological interventions for the production of forskolin, an active compound from the medicinal plant,Coleus forskohlii
    Pulukkunadu Thekkeveedu Roshni, Punchappady Devasya Rekha (2024)
15. Butyrate and Forskolin Augment Host Defense, Barrier Function, and Disease Resistance Without Eliciting Inflammation.
    Kelsy Robinson, Qing Yang, Hong Li, Long Zhang, Bridget Aylward, Ryan J Arsenault, Guolong Zhang (2021) - Frontiers in nutrition
16. Mg2+ supplementation treats secretory diarrhea in mice by activating calcium-sensing receptor in intestinal epithelial cells.
    Livia de Souza Goncalves, Tifany Chu, Riya Master, Parth D Chhetri, Qi Gao, Onur Cil (2024) - The Journal of clinical investigation
17. Hyperphosphorylation of PP2A in colorectal cancer and the potential therapeutic value showed by its forskolin-induced dephosphorylation and activation.
    Ion Cristóbal, Raúl Rincón, Rebeca Manso, Juan Madoz-Gúrpide, Cristina Caramés, Laura del Puerto-Nevado, Federico Rojo, Jesús García-Foncillas (2014) - Biochimica et biophysica acta
18. Assessing the Performance of Daily Intake of a Homotaurine, Carnosine, Forskolin, Vitamin B2, Vitamin B6, and Magnesium Based Food Supplement for the Maintenance of Visual Function in Patients with Primary Open Angle Glaucoma.
    Teresa Rolle, Laura Dallorto, Stefania Rossatto, Daniela Curto, Raffaele Nuzzi (2020) - Journal of ophthalmology
19. Coleus forskohlii extract induces hepatic cytochrome P450 enzymes in mice.
    Nantiga Virgona, Kaori Yokotani, Yuko Yamazaki, Fumio Shimura, Tsuyoshi Chiba, Yuko Taki, Shizuo Yamada, Kazumasa Shinozuka, Masatsune Murata, Keizo Umegaki (2012) - Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association
20. Forskolin enhances in vivo bone formation by human mesenchymal stromal cells.
    Joyce Doorn, Ramakrishnaiah Siddappa, Clemens A van Blitterswijk, Jan de Boer (2012) - Tissue engineering. Part A

This article summarizes published research for educational purposes. It is not medical advice. Talk to your doctor before starting, stopping, or changing any supplement or medication.